Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

@article{Ziemssen2002GlatiramerAT,
  title={Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.},
  author={Tjalf Ziemssen and Tania Kuempfel and Wolfgang E. F. Klinkert and Oliver Neuhaus and Reinhard Hohlfeld},
  journal={Brain : a journal of neurology},
  year={2002},
  volume={125 Pt 11},
  pages={2381-91}
}
The clinical effects of glatiramer acetate (GA), an approved therapy for multiple sclerosis, are thought to be largely mediated by a T-helper 1 (TH1) to T-helper 2 (TH2) shift of GA-reactive T-lymphocytes. Current theories propose that activated GA-reactive TH2 cells penetrate the CNS, release anti-inflammatory cytokines such as interleukin (IL)-4, IL-5 and IL-10, and thus inhibit neighbouring inflammatory cells by a mechanism termed 'bystander suppression'. We demonstrate that both GA-specific… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

Similar Papers

Loading similar papers…